GLP-1 Advisor | One Day MD

Last updated: October 13, 2026 | Evidence reviewed by OneDayMD editorial research team Retatrutide vs tirzepatide is one of the most important emerging comparisons in obesity medicine. Both medications act on hormone pathways involved in appetite, food intake and glucose metabolism, but retatrutide activates three receptors instead of two. The clinical results are promising. In the Phase 3 TRIUMPH-1 trial published in The New England Journal of Medicine on September 29, 2026, retatrutide produced an average weight reduction of 25.0% at 80 weeks at the 12 mg dose when analyzed using the treatment-regimen estimand. In the separate SURMOUNT-1 trial, tirzepatide produced an average reduction of 20.9% at 72 weeks at the 15 mg dose under a comparable treatment-regimen approach. However, these are results from separate clinical trials, not a direct head-to-head comparison. Retatrutide also remains investigational and is not approved for routine prescribing. Key takeaway: ...

Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide: what is and isn't known Safety, side effects and compounding risks Evidence grades (CEBM) Explore the full GLP-1 & peptide library Malaysia & Singapore readers Usi...

OneDayMD Research Team · Updated October 13, 2026 · Evidence-based health guide GLP-1-based medicines have changed the treatment of obesity and type 2 diabetes. But getting good results involves more than taking an injection or watching the number on the scale fall. Nutrition, muscle preservation, side-effect management, health monitoring and a realistic long-term plan all matter. This guide follows the full treatment journey: deciding whether medication is appropriate, preparing for treatment, navigating the first few months, protecting nutritional and musculoskeletal health, maintaining benefits and planning for situations in which treatment must or may be stopped. It covers semaglutide, liraglutide and tirzepatide, among other medicines in this therapeutic category. The available products, indications, formulations and prescribing rules differ between countries. The essential takeaways Treat obesity as a long-term healt...